The United States Clinical Laboratory Services Market is expected to reach a valuation of US$ 125.6 Bn by 2030 from 93.0 billion in 2022 at a CAGR of 4.2% Over the Forecast Period 2023-2030.
Clinical laboratory services play an essential role in healthcare, supporting patient care across the continuum of health, from prevention and early detection to diagnosis and treatment. The services are delivered in various settings, including hospitals, clinics, private laboratories, and research institutions.
The diagnostic and testing procedures provided in the US clinical laboratory services market include a vast range of tests that can identify and measure different substances and biomarkers, including blood, urine, and tissue samples. These tests can help diagnose conditions such as infections, cancer, genetic disorders, and autoimmune diseases. In addition to diagnosing illnesses, clinical laboratory services also play a critical role in monitoring disease progression and treatment efficacy. For instance, laboratory tests can be used to monitor blood sugar levels in diabetic patients or measure viral load in patients with HIV/AIDS to assess the effectiveness of treatment.
Moreover, clinical laboratory services market have become increasingly important in the context of the COVID-19 pandemic. Testing for COVID-19 has been essential in tracking and controlling the spread of the virus. Clinical laboratory services have been at the forefront of COVID-19 testing, developing and deploying diagnostic tests that have enabled rapid and accurate detection of the virus.
To Get more Insights, Request A Free Sample
Chronic diseases are the leading cause of death worldwide, accounting for 71% of deaths globally. According to the World Health Organization (WHO), chronic diseases such as cardiovascular disease, cancer, chronic respiratory disease, and diabetes are responsible for approximately 41 million deaths every year, which is equivalent to 71% of all deaths globally.
The incidence of chronic diseases is on the rise globally, and this trend is expected to continue in the coming years in the clinical laboratory services market. According to a report by the Global Burden of Disease (GBD) study, the number of people living with chronic diseases has increased by 40% in the past 30 years. One of the primary drivers of the increase in chronic diseases is an aging population. The global population is aging, and this has led to an increase in chronic diseases such as cardiovascular disease, cancer, and diabetes. The WHO estimates that by 2050, the global population aged 60 years and over will reach 2 billion, up from 900 million in 2015.
Unhealthy lifestyles and environmental factors are also contributing to the rise in chronic diseases in the clinical laboratory services market. Poor diet, lack of physical activity, and tobacco use are major risk factors for chronic diseases. According to the WHO, more than 1.9 billion adults are overweight, and of these, over 650 million are obese. Obesity is a significant risk factor for chronic diseases such as diabetes, cardiovascular disease, and cancer.
Urbanization is another factor contributing to the rise in chronic diseases. The global middle class is growing, and with urbanization, there is a shift towards a more sedentary lifestyle. This has resulted in an increase in obesity rates and cases of diseases such as diabetes.
Digital pathology platforms offer several advantages over traditional pathology methods. For example, digital pathology enables the digitization of tissue samples and other specimens, which can then be analyzed and shared electronically. This allows for faster turnaround times, improved accuracy, and increased efficiency, leading to better patient outcomes.
The use of digital pathology platforms is particularly important in the diagnosis and treatment of cancer. Digital pathology allows for more precise and timely diagnoses, which can lead to earlier detection and better treatment outcomes. It also enables the evaluation of the efficacy of new drugs and the development of companion diagnostics, which can be used to identify patients who are most likely to benefit from a particular treatment.
Moreover, the COVID-19 pandemic has further accelerated the adoption of digital pathology platforms in the clinical laboratory services market. The pandemic has increased the demand for remote diagnosis and telemedicine, and digital pathology has been instrumental in meeting this demand. Digital pathology platforms have enabled pathologists to remotely analyze and diagnose specimens, reducing the need for physical interactions and increasing efficiency.
The growing adoption of digital pathology platforms is also driving the development of artificial intelligence (AI) and machine learning (ML) technologies in the clinical laboratory services market. AI and ML technologies can be used to analyze large amounts of data and identify patterns, which can then be used to improve diagnoses and treatments.
While it is true that the shift towards home-based and point-of-care testing procedures has increased in recent years, it is important to note that this trend has also created new opportunities for the clinical laboratory services market.
Point-of-care testing (POCT) offers several benefits over traditional lab-based testing procedures. POCT can provide rapid results, allowing for faster diagnosis and treatment, and reducing the need for patients to return for follow-up appointments. It can also reduce the risk of contamination and infection transmission by eliminating the need for transportation of samples to a lab. Moreover, POCT can improve patient outcomes by facilitating earlier diagnoses, particularly for conditions such as diabetes, cardiovascular disease, and infectious diseases.
Home-based testing, on the other hand, offers greater convenience to patients who may have difficulty accessing traditional laboratory services. This can be particularly beneficial for patients who live in rural or remote areas, who may not have easy access to lab-based testing facilities. Home-based testing can also be a more cost-effective alternative for patients, as it eliminates the need for travel to a laboratory and reduces the overall cost of testing.
Furthermore, the shift towards home-based and point-of-care testing procedures has also created new opportunities for the clinical laboratory services market. Clinical laboratories can partner with manufacturers of point-of-care testing devices to provide testing services, or they can offer remote monitoring and consultation services to patients who are using home-based testing kits.
Technological advancements in disease diagnostics is the trend in the clinical laboratory services market. Advanced molecular diagnostic techniques such as Next-Generation Sequencing (NGS), real-time PCR, molecular cartridges, and PCR coupled with mass spectrometry are increasingly being recognized for their capabilities in disease diagnosis and identification of several pathogens. These techniques allow for the rapid and accurate identification of pathogens, even in low-abundance samples, enabling clinicians to diagnose diseases at an earlier stage and with greater precision. The growing adoption of these techniques among key end-users, including healthcare providers such as hospitals and microbial and clinical centers, research laboratories, and pharmaceutical and biotechnology companies, is driven by several factors. These include the need for rapid and accurate diagnosis of infectious diseases, the ability to analyze multiple samples in a single run, and the ability to perform targeted sequencing and analysis of specific genes or regions of interest. For example, the development of Next-Generation Sequencing (NGS) technology has revolutionized the field of genomics by enabling the rapid and cost-effective analysis of large volumes of genetic data.
The clinical laboratory services market is segmented into Clinical Chemistry Testing, Microbiology Testing, Hematology Testing, Immunology Testing, Cytology Testing, Genetic Testing, and Drug of Abuse Testing. The clinical chemistry testing segment holds the highest market share in 2022, registering a revenue of US$ 31.1 Bn due to numerous clinical chemistry tests in the US, along with the high adoption of new technologies and the emergence of point-of-care testing methods in the country.
On the basis of application, the clinical laboratory services market is segmented into Bioanalytical & Lab Chemistry Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Drug Discovery & Development Related Services, and Others. The bioanalytical & lab chemistry services segment was valued at US$ 55.0 billion in 2022 and is expected to reach US$ 71.9 billion by 2030. Toxicology testing services segment is anticipated to grow at the highest CAGR of 5.2% over the forecast period.
To Understand More About this Research: Request A Free Sample
In terms of end user, the clinical laboratory services market is segmented into Hospitals, Government Agencies, Physicians, Clinicals Labs, Pharmaceutical Companies, and Others. The hospitals segment holds the largest share in 2022, registering a revenue of US$ 40.8 billion. Government agencies segment is anticipated to grow at the highest CAGR of 5.0% over the forecast period.
The clinical laboratory services market is highly competitive, with companies such as Qiagen, Bioreference labs, Sonic Healthcare, SYNLAB, Opko Health, Abbott, Charles River Laboratories, Roche Laboratories, Almac Group, Siemens Healthcare Limited, Astrazeneca, Novartis Laboratories, Merck Inc., Pfizer Inc, Eli Lilly, and Eurofins holding around 25% of the market share.
The U.S. Clinical Laboratory Services market is sub-segmented into:
By Test Type segment, the U.S. Clinical Laboratory Services market is sub-segmented into:
By Application segment, the U.S. Clinical Laboratory Services market is sub-segmented into:
By End User segment, the U.S. Clinical Laboratory Services market is sub-segmented into:
| Report Attribute | Details |
|---|---|
| Market Size Value in 2022 | US$ 93.0 Billion |
| Expected Revenue in 2030 | US$ 125.6 Billion |
| Historic Data | 2018-2021 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Unit | Value (USD Bn) |
| CAGR | 4.2% (2023-2030) |
| Segments covered | By Test Type, By Application, By End-User |
| Key Companies | Qiagen Inc., Opko Health, Inc., Abbott Laboratories, Charles River Laboratories, Johnson & Johnson, Roche Laboratories, Pfizer Inc, Eli Lilly, Novartis Laboratories, Merck Inc., Astrazeneca, Arup Laboratories, Davita, Inc., Siemens Healthcare Limited, Viapath Group Llp, Almac Group, Neogenomics Laborateries, Eurofins Scientific, UNILABS, SYNLAB International GmbH, H.U. Groups Holdings, Inc., Sonic Healthcare, ACM Global Laboratories, Amedes Holding GmbH, BioReference Laboratories, Inc., Other Prominent Players |
| Customization Scope | Get your customized report as per your preference. Ask for customization |
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.
SPEAK TO AN ANALYST
.png)
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0323376 | Delivery: 2 to 4 Hours 
.svg)
